MedTrace Logo

Predicting the Efficacy in Advanced Gastric Cancer.

NCT06490055 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 162

Last updated 2025-07-18

No results posted yet for this study

Summary

With advances in chemotherapy for gastric cancer, it is important to identify patients who will respond effectively to specific therapies. This longitudinal study aimed to establish a liquid-biopsy assay that can predict response to ramucirumab plus paclitaxel therapy in patients with advanced gastric cancer.

Conditions

Interventions

DRUG

Paclitaxel

Gastric cancer second-line Chemotherapy (paclitaxel plus ramucirumab)

Sponsors & Collaborators

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Koichi Takiguchi, PhD · City of Hope Medical Center

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2025-02-18
Completion
2025-07-01

Countries

  • United States
  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06490055 on ClinicalTrials.gov